Literature DB >> 24464697

Is there any value in measuring faecal calprotectin in Clostridium difficile positive faecal samples?

Simon J Whitehead1, Kate E Shipman1, Mike Cooper2, Clare Ford1, Rousseau Gama3,1.   

Abstract

Markers of intestinal inflammation have been proposed for inclusion in Clostridium difficile diagnostic algorithms. Faecal calprotectin (f-Cp), a sensitive marker of intestinal inflammation, was evaluated for utility in C. difficile diagnosis in the hospital setting. One hundred and twenty C. difficile positive and 99 C. difficile negative faecal samples of hospital-acquired diarrhoea were analysed for f-Cp using a quantitative ELISA. C. difficile positivity was confirmed using ELISAs for either toxins (n = 45) or glutamate dehydrogenase (GDH) with toxin gene confirmation (n = 75). Non-parametric ANOVA (Kruskal-Wallis) was used for data analysis. C. difficile positive samples had higher (P<0.05) median (interquartile range) f-Cp levels; 336 µg g(-1) (208-536) for toxin and 249 µg g(-1) (155-498) for GDH and toxin gene positive compared with 106 µg g(-1) (46-176) for C. difficile and culture-negative faecal samples. Five C. difficile positive samples were f-Cp negative (<50 µg g(-1)). A f-Cp concentration >50 µg g(-1) was 96 % sensitive and 26 % specific for C. difficile, with area under the ROC curve of 0.82. There is no role for f-CP alone in predicting C. difficile infection in hospital-acquired diarrhoea due to its low specificity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464697     DOI: 10.1099/jmm.0.067389-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.

Authors:  F Barbut; C Gouot; N Lapidus; L Suzon; R Syed-Zaidi; V Lalande; C Eckert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-12       Impact factor: 3.267

2.  Usefulness of Adjunctive Fecal Calprotectin and Serum Procalcitonin in Individuals Positive for Clostridium difficile Toxin Gene by PCR Assay.

Authors:  Kristin Y Popiel; Romina Gheorghe; Jennifer Eastmond; Mark A Miller
Journal:  J Clin Microbiol       Date:  2015-09-09       Impact factor: 5.948

3.  2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Authors:  Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

4.  Fecal calprotectin concentrations in cancer patients with Clostridium difficile infection.

Authors:  Taojun He; Samuel E Kaplan; Luz A Gomez; Xuedong Lu; Lakshmi V Ramanathan; Mini Kamboj; Yi-Wei Tang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-21       Impact factor: 3.267

5.  Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection.

Authors:  Jieun Kim; Heejung Kim; Hyun Ju Oh; Hyung Sun Kim; Youn Jee Hwang; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee
Journal:  Ann Lab Med       Date:  2017-01       Impact factor: 3.464

6.  The value of fecal calprotectin in Clostridioides difficile infection: A systematic review.

Authors:  Bao-Jiang Wen; Li-Ger Te; Xiao-Xuan Liu; Jian-Hong Zhao
Journal:  Front Physiol       Date:  2022-08-03       Impact factor: 4.755

7.  Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.

Authors:  Andrew Swale; Fabio Miyajima; Paul Roberts; Amanda Hall; Margaret Little; Mike B J Beadsworth; Nick J Beeching; Ruwanthi Kolamunnage-Dona; Chris M Parry; Munir Pirmohamed
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

8.  Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.

Authors:  Avi Peretz; Linda Tkhawkho; Nina Pastukh; Diana Brodsky; Chen Namimi Halevi; Orna Nitzan
Journal:  BMC Infect Dis       Date:  2016-06-22       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.